688247 宣泰医药
已收盘 04-30 15:00:00
资讯
新帖
简况
宣泰医药（688247）披露2025年年度报告，4月30日股价上涨1.53%
证券之星 · 18:07
宣泰医药（688247）披露2025年年度报告，4月30日股价上涨1.53%
图解宣泰医药年报：第四季度单季净利润同比下降145.49%
证券之星 · 00:59
图解宣泰医药年报：第四季度单季净利润同比下降145.49%
每周股票复盘：宣泰医药（688247）股东减持243.69万股，占总股本0.5376%
证券之星 · 04-19
每周股票复盘：宣泰医药（688247）股东减持243.69万股，占总股本0.5376%
4月14日宣泰医药发布公告，股东减持243.69万股
证券之星 · 04-14
4月14日宣泰医药发布公告，股东减持243.69万股
每周股票复盘：宣泰医药（688247）现2笔大宗交易机构净买入200.7万元
证券之星 · 04-12
每周股票复盘：宣泰医药（688247）现2笔大宗交易机构净买入200.7万元
4月8日宣泰医药现2笔大宗交易 机构净买入200.7万元
证券之星 · 04-08
4月8日宣泰医药现2笔大宗交易 机构净买入200.7万元
每周股票复盘：宣泰医药（688247）授出483.4万股限制性股票
证券之星 · 04-05
每周股票复盘：宣泰医药（688247）授出483.4万股限制性股票
宣泰医药（688247）披露关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告，4月2日股价下跌0.61%
证券之星 · 04-02
宣泰医药（688247）披露关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告，4月2日股价下跌0.61%
宣泰医药(688247.SH)向64名激励对象授予483.4万股限制性股票
智通财经 · 04-01
宣泰医药(688247.SH)向64名激励对象授予483.4万股限制性股票
每周股票复盘：宣泰医药（688247）高管李方立增持3747股
证券之星 · 03-29
每周股票复盘：宣泰医药（688247）高管李方立增持3747股
宣泰医药（688247）披露2025年限制性股票激励计划（草案修订稿），3月26日股价下跌1.62%
证券之星 · 03-26
宣泰医药（688247）披露2025年限制性股票激励计划（草案修订稿），3月26日股价下跌1.62%
宣泰医药：3月23日高级管理人员李方立增持股份合计3747股
证券之星 · 03-23
宣泰医药：3月23日高级管理人员李方立增持股份合计3747股
宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书
智通财经 · 03-17
宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书
宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%
证券之星 · 03-16
宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%
宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准
智通财经 · 03-13
宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准
每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准
证券之星 · 03-08
每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准
宣泰医药：3月4日高管李方立增持股份合计2100股
证券之星 · 03-05
宣泰医药：3月4日高管李方立增持股份合计2100股
宣泰医药(688247.SH)：维生素K1片获得美国FDA批准
智通财经 · 03-02
宣泰医药(688247.SH)：维生素K1片获得美国FDA批准
宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%
智通财经 · 02-27
宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%
宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购
智通财经网 · 02-10
宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购
加载更多
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是美沙拉秦肠溶片、泊沙康唑肠溶片、熊去氧胆酸胶囊、盐酸安非他酮缓释片、碳酸司维拉姆片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。公司荣膺“2025中国医药CDMO企业20强”。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":9.3,"timestamp":1777532400000,"preClose":9.16,"halted":0,"volume":2567592,"delay":0,"changeRate":0.0153,"floatShares":453000000,"shares":453000000,"eps":0.0961,"marketStatus":"已收盘","change":0.14,"latestTime":"04-30 15:00:00","open":9.23,"high":9.38,"low":9.15,"amount":23870300,"amplitude":0.0251,"askPrice":9.3,"askSize":113,"bidPrice":9.29,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.0961,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":10.08,"lowLimit":8.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":3.22,"roa":"--","peRate":96.774194,"roe":"1.27%","epsLYR":0.11,"committee":-0.57224,"marketValue":4216000000,"turnoverRate":0.0057,"status":0,"afterMarket":{"amount":0,"volume":0,"close":9.3,"buyVolume":0,"sellVolume":0,"time":1777534437559,"indexStatus":"已收盘 04-30 15:30:00","preClose":9.16},"floatMarketCap":4216000000},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2631665687","title":"宣泰医药（688247）披露2025年年度报告，4月30日股价上涨1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631665687","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631665687?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:07","pubTimestamp":1777543636,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，宣泰医药报收于9.3元，较前一交易日上涨1.53%，最新总市值为42.16亿元。该股当日开盘9.23元，最高9.38元，最低9.15元，成交额达2387.03万元，换手率为0.57%。公司于2026年4月30日披露《2025年年度报告》。报告显示，公司2025年实现营业收入446,568,888.08元，同比下降12.71%；归属于上市公司股东的净利润为47,482,814.69元，同比下降62.82%；归属于上市公司股东的扣除非经常性损益的净利润为31,333,993.96元，同比下降72.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631544237","title":"图解宣泰医药年报：第四季度单季净利润同比下降145.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631544237","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631544237?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:59","pubTimestamp":1777481964,"startTime":"0","endTime":"0","summary":"证券之星消息，宣泰医药2025年年报显示，当年度公司主营收入4.47亿元，同比下降12.71%；归母净利润4748.28万元，同比下降62.82%；扣非净利润3133.4万元，同比下降72.51%；其中2025年第四季度，公司单季度主营收入1.15亿元，同比下降22.75%；单季度归母净利润-1597.97万元，同比下降145.49%；单季度扣非净利润-2254.67万元，同比下降177.94%；负债率10.16%，投资收益991.14万元，财务费用-153.64万元，毛利率39.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000003148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628751596","title":"每周股票复盘：宣泰医药（688247）股东减持243.69万股，占总股本0.5376%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628751596","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628751596?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:35","pubTimestamp":1776540909,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，宣泰医药报收于9.39元，较上周的9.53元下跌1.47%。本周，宣泰医药4月15日盘中最高价报9.63元。4月17日盘中最低价报9.3元。宣泰医药当前最新总市值42.57亿元，在化学制药板块市值排名111/150，在两市A股市值排名3863/5198。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627544511","title":"4月14日宣泰医药发布公告，股东减持243.69万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627544511","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627544511?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:01","pubTimestamp":1776168077,"startTime":"0","endTime":"0","summary":"证券之星消息，4月14日宣泰医药发布公告《宣泰医药:简式权益变动报告书》，其股东Finer Pharma Inc.于2026年3月11日至2026年4月14日间合计减持243.69万股，占公司目前总股本的0.5376%，变动期间该股股价下跌4.35%，截止4月14日收盘报9.45元。股东增减持详情见下表：根据宣泰医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400034181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122108","title":"每周股票复盘：宣泰医药（688247）现2笔大宗交易机构净买入200.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122108","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122108?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:05","pubTimestamp":1775930713,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，宣泰医药（688247）报收于9.53元，较上周的9.51元上涨0.21%。本周，宣泰医药4月8日盘中最高价报9.9元。4月7日盘中最低价报9.41元。宣泰医药当前最新总市值43.2亿元，在化学制药板块市值排名112/150，在两市A股市值排名3777/5196。本周关注点来自交易信息汇总：4月8日宣泰医药现2笔大宗交易，机构净买入200.7万元交易信息汇总4月8日宣泰医药现2笔大宗交易，机构净买入200.7万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625238917","title":"4月8日宣泰医药现2笔大宗交易 机构净买入200.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625238917","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625238917?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:53","pubTimestamp":1775642010,"startTime":"0","endTime":"0","summary":"证券之星消息，4月8日宣泰医药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交4460.0手，折价成交2笔。该股近期无解禁股上市。截至2026年4月8日收盘，宣泰医药(688247)报收于9.76元，上涨0.62%，换手率0.86%，成交量3.89万手，成交额3791.89万元。该股近半年内有股东持股变动，合计净减持321.8万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800028188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625061136","title":"每周股票复盘：宣泰医药（688247）授出483.4万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2625061136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625061136?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:53","pubTimestamp":1775332388,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，宣泰医药报收于9.51元，较上周的9.48元上涨0.32%。本周关注点公司公告汇总：宣泰医药向64名激励对象首次授予483.40万股限制性股票，授予价格为5.71元/股。2025年限制性股票激励计划首次授予激励对象共计不超过64人。首次授予合计483.40万股，占公司股本总额1.07%，股票类型为第二类限制性股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500001176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624391688","title":"宣泰医药（688247）披露关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告，4月2日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624391688","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624391688?lang=zh_cn&edition=full","pubTime":"2026-04-02 23:13","pubTimestamp":1775142792,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，宣泰医药报收于9.8元，较前一交易日下跌0.61%，最新总市值为44.43亿元。公司于近日发布《关于向2025年限制性股票激励计划激励对象首次授予限制性股票的公告》。公告显示，上海宣泰医药科技股份有限公司于2026年4月1日召开董事会，确定向64名激励对象首次授予483.40万股限制性股票，授予价格为5.71元/股，股票来源为定向发行或二级市场回购。本次授予的限制性股票自授予日起24个月后分三期归属，有效期最长不超过72个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200043402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551320","title":"宣泰医药(688247.SH)向64名激励对象授予483.4万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551320","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624551320?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:17","pubTimestamp":1775045849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，公司审议通过了《关于向激励对象首次授予限制性股票的议案》，确定2026年4月1日为首次授予日，以人民币5.71元/股的授予价格向64名激励对象授予483.4万股限制性股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623358513","title":"每周股票复盘：宣泰医药（688247）高管李方立增持3747股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623358513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623358513?lang=zh_cn&edition=full","pubTime":"2026-03-29 05:04","pubTimestamp":1774731858,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，宣泰医药报收于9.48元，较上周的9.43元上涨0.53%。本周，宣泰医药3月27日盘中最高价报9.5元。股本股东变化高管增减持2026年3月23日，宣泰医药高级管理人员李方立增持公司股份3747.0股，占公司总股本的0.0008%。当日公司股价下跌5.94%，收盘价为8.87元。本次激励计划拟授予不超过604.00万股限制性股票，占公司总股本的1.33%，其中首次授予占比80.03%，预留19.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622913853","title":"宣泰医药（688247）披露2025年限制性股票激励计划（草案修订稿），3月26日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622913853","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622913853?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:30","pubTimestamp":1774517447,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，宣泰医药报收于9.11元，较前一交易日下跌1.62%，最新总市值为41.3亿元。该股当日开盘9.24元，最高9.37元，最低9.07元，成交额达1222.47万元，换手率为0.29%。本次激励计划拟授予不超过604.00万股限制性股票，占公司总股本的1.33%，其中首次授予占比80.03%，预留19.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621033557","title":"宣泰医药：3月23日高级管理人员李方立增持股份合计3747股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621033557","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621033557?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:01","pubTimestamp":1774267282,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月23日市场公开信息、上市公司公告及交易所披露数据整理，宣泰医药最新董监高及相关人员股份变动情况：2026年3月23日公司高级管理人员李方立共增持公司股份3747.0股，占公司总股本为0.0008%。宣泰医药近半年内的董监高及核心技术人员增减持详情如下：宣泰医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入300.28万，融资余额增加；融券净流入1200.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300034950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620844164","title":"宣泰医药(688247.SH)：宣泰®番茄红葡萄籽提取物片获得国产保健食品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620844164","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620844164?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:41","pubTimestamp":1773733281,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 宣泰医药(688247.SH)发布公告，近日，公司收到国家市场监督管理总局核准签发的《国产保健食品注册证书》，公司产品宣泰®番茄红葡萄籽提取物片获得批准注册。本次宣泰®番茄红葡萄籽提取物片获得《国产保健食品注册证书》，符合公司延伸至大健康领域的战略规划，有利于进一步丰富公司的产品线，提升公司在保健食品领域的竞争力，对公司未来的经营业绩产生积极的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619456457","title":"宣泰医药（688247）披露2026年第一次临时股东会通知，3月16日股价上涨1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619456457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619456457?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:25","pubTimestamp":1773653130,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，宣泰医药报收于9.85元，较前一交易日上涨1.34%，最新总市值为44.65亿元。该股当日开盘9.83元，最高9.86元，最低9.73元，成交额达1717.93万元，换手率为0.39%。近日，上海宣泰医药科技股份有限公司发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司将于2026年4月1日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式，股权登记日为2026年3月25日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600024112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619195077","title":"宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195077","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619195077?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:32","pubTimestamp":1773397933,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司参与合作开发的恩扎卢胺片收到国家药品监督管理局核准签发的《药品注册证书》，批准恩扎卢胺片上市。恩扎卢胺片是一种雄激素受体抑制剂，本次获批的适应症为：适用于“转移性激素敏感性前列腺癌(mHSPC)成年患者;有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者;雄激素剥夺治疗(ADT)失败后无症状或有轻微症状且未接受化疗的转移性去势抵抗性前列腺癌(CRPC)成年患者的治疗”。此外，该产品已于2025年6月获得美国食品药品监督管理局暂时批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：合作产品恩扎卢胺片获得国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663872","title":"每周股票复盘：宣泰医药（688247）维生素K1片获美FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663872?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:02","pubTimestamp":1772910135,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，宣泰医药报收于9.74元，较上周的10.28元下跌5.25%。本周，宣泰医药3月2日盘中最高价报10.12元。本周关注点公司公告汇总：宣泰医药维生素K1片获美国FDA批准，具备美国市场销售资格。股本股东变化高管增减持2026年3月4日，公司高级管理人员李方立增持宣泰医药股份2100.0股，占公司总股本0.0005%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617412375","title":"宣泰医药：3月4日高管李方立增持股份合计2100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617412375","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617412375?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:01","pubTimestamp":1772712109,"startTime":"0","endTime":"0","summary":"证券之星消息，根据3月5日市场公开信息、上市公司公告及交易所披露数据整理，宣泰医药最新董监高及相关人员股份变动情况：2026年3月4日公司高级管理人员李方立共增持公司股份2100.0股，占公司总股本为0.0005%。宣泰医药近半年内的董监高及核心技术人员增减持详情如下：宣泰医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入173.04万，融资余额增加；融券净流入1.56万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500035239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616389979","title":"宣泰医药(688247.SH)：维生素K1片获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389979","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616389979?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:08","pubTimestamp":1772438890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司收到美国食品药品监督管理局(以下简称“美国FDA”)的通知，公司向美国FDA申报的维生素K1片的简略新药申请(以下简称“ANDA”，即美国仿制药申请)获得正式批准。本次维生素K1片获得美国FDA批准，标志着具备了在美国市场销售该产品的资格，将有利于公司未来不断扩大在美国市场的销售规模，丰富产品梯队，对公司的长期经营产生积极的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：维生素K1片获得美国FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614833523","title":"宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833523","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833523?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:59","pubTimestamp":1772182751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布2025年度业绩快报，报告期，公司实现营业总收入44,649.88万元，同比下降12.73%;归属于母公司所有者的净利润为4894.63万元，同比下降61.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"宣泰医药(688247.SH)2025年度归母净利润4894.63万元 同比下降61.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610611679","title":"宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610611679","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610611679?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:35","pubTimestamp":1770708905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布公告，近日，公司参与了国家组织集采第1-8批协议期满品种接续采购的申报，根据国家组织集采药品协议期满品种接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果表》显示，公司产品熊去氧胆酸胶囊拟中选本次接续采购。本次第1-8批协议期满品种接续采购，采购周期中，医疗机构将优先使用中标药品，并确保完成约定采购量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777558546535,"stockEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.1167},{"period":"6month","weight":-0.1658},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0557}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7965人(较上一季度增加2.36%)","perCapita":"56916股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是美沙拉秦肠溶片、泊沙康唑肠溶片、熊去氧胆酸胶囊、盐酸安非他酮缓释片、碳酸司维拉姆片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。公司荣膺“2025中国医药CDMO企业20强”。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}